Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 625-633

  Heneweer, Carola ^a,b   Holland, Jason P ^a   Divilov, Vadim ^a   Carlin, Sean ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

89Zr; Albumin; Contrast enhanced ultrasound; Enhanced permeability and retention (EPR) effect; Positron emission tomography; Prostate cancer

Indexed keywords

DESFERRIOXAMINE MOUSE SERUM ALBUMIN ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SPECIFICITY; DRUG STABILITY; DRUG UPTAKE; ECHOGRAPHY; ENHANCED PERMEABILITY AND RETENTION EFFECT; EX VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE PERFUSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; AUTORADIOGRAPHY; DEFEROXAMINE; DRUG STABILITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON CHELATING AGENTS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; SERUM ALBUMIN; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; ZIRCONIUM;

EID: 79954571631     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083998     Document Type: Article

References (28)

1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-6392. (Pubitemid 17221789)
2. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46:169-185.
3. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem.1992;3:351-362.
4. Yokoyama M, Okano T, Sakurai Y, Kataoka K. Improved synthesis of adriamycin- conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin. J Control Release. 1994;32:269-277.
5. Duncan R. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009;61:1131-1148.
6. Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action. J Drug Target. 2007;15:518-530. (Pubitemid 47209052)
7. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74:47-61. (Pubitemid 32727608)
8. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. March 18, 2010 [Epub ahead of print].
9. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem. 2010;21:797-802.
10. Levick JR. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 1981;24:1550-1560. (Pubitemid 12253287)
11. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself: Implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77-100. (Pubitemid 27362424)
12. Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281. (Pubitemid 39662684)
13. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
14. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacokinetic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr- DFO-trastuzumab. PLoS ONE. 2010;5:e8859.
15. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr- DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
16. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-483. (Pubitemid 28090220)
17. Kim J, Bronson CL, Hayton WL, et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2006;290:G352-G360.
18. Holland JP, Lewis Jason S. Zirconium-89 chemistry in the design of novel radiotracers for immuno-PET. In:Mazzi U, Eckelman WC, VolkertWA, eds. Technetium and Other Radiometals in Chemistry and Medicine. Padova, Italy: Servizi Grafici Editoriali snc; 2010:187-192.
19. Anderson CJ, Schwarz SW, Connett JM, et al. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. J Nucl Med. 1995;36:850-858.
20. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis.2006;27:1-22. (Pubitemid 43032978)
21. Pienta KJ, Abate-Shen C, Agus DB, et al. The current state of preclinical prostate cancer animal models. Prostate. 2008;68:629-639. (Pubitemid 351614641)
22. Cheung CP, Yu S, Wong KB, et al. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab. 2005;90:1830-1844. (Pubitemid 40464058)
23. Niu Y, Yeh S, Miyamoto H, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 2008;68:7110-7119.
24. Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer. 2001;92:718-724. (Pubitemid 32385716)
25. Neumann E, Frei E, Funk D, et al. Native albumin for targeted drug delivery. Expert Opin Drug Del. 2010;7:915-925.
26. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-1416. (Pubitemid 28193601)
27. Brown JM. The hypoxic cell: A target for selective cancer therapy-eighteenth Bruce F. Cain memorial award lecture. Cancer Res. 1999;59:5863-5870. (Pubitemid 30004940)
28. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437-447. (Pubitemid 38745529)